Two pieces of news this time both aim at slowing Parkinson’s rather than just easing symptoms after the fact. One is a vaccine that trains the immune system to clear a toxic protein believed to drive the disease. The other is an oral drug aimed at brain inflammation. Neither is something you can be prescribed yet, but both are worth writing up because they point at the disease itself, not only its symptoms.
An experimental vaccine that clears a toxic protein got FDA fast-track status
🔍 What happened
The U.S. Food and Drug Administration (FDA) granted fast-track status — a designation meant to speed up the development and review of promising treatments for serious conditions — to ACI-7104, an experimental vaccine developed by the Swiss biopharmaceutical company AC Immune. The FDA also cleared an application that lets an ongoing European trial expand to sites in the U.S. ACI-7104 works as an active immunotherapy: it uses a lab-made protein that resembles alpha-synucleinA protein in nerve cells. Clumps of it, misfolded, are believed to damage neurons and drive Parkinson's disease. Antibody treatments and vaccines aimed at clearing it are an active area of research.Learn more to train the immune system to produce antibodies against its toxic, clumped form, with the goal of slowing or preventing further nerve cell loss.
The fast-track decision was supported by interim results from the ongoing Phase 2The stage that gathers preliminary data on whether a drug actually works, while safety checks continue.Learn more trial (called VacSYn), in the first 34 participants: the vaccine was safe and well tolerated, and everyone who received it developed antibodies against clumped alpha-synuclein. Among those given a higher dose, the level of clumped alpha-synuclein measured in spinal fluid fell by about 51% after the initial course of treatment. The most common side effects were injection-site reactions (56%), headache (15%) and fatigue (12%), described as generally mild and short-lived.
✅ If you have Parkinson’s
This is a vaccine aimed at the disease process itself — clearing a toxic protein — rather than at managing symptoms after the fact. The ongoing trial is testing it in about 150 adults, ages 40 to 75, who are within roughly their first year after diagnosis. Full results from this first stage are expected in the second half of 2026.
🙋 If you’re a care partner
“Vaccine” can sound like something closer to done than it is — this one is still an injection given over 18 months as part of an ongoing trial, not a one-time shot. If you’re curious whether a trial like this is recruiting near you, the Clinical Trials & Research section is worth checking from time to time.
A new oral drug eased both movement and non-movement symptoms in an early trial
🔍 What happened
Bezisterim, an oral drug developed by the biotech company BioVie, showed significant improvement over a placebo in a Phase 2 trial called SUNRISE-PD. The trial enrolled 57 people with early-stage Parkinson’s who had not yet started levodopa, giving them bezisterim or a placebo for about three months. Unlike levodopa, which supplies the brain with more raw material to make dopamine but does not change the disease’s course, bezisterim is designed to dampen brain inflammation, which is thought to play a role in driving Parkinson’s forward.
The trial’s main goal — showing a change in blood markers of inflammation — was met, and bezisterim also significantly outperformed the placebo on the MDS-UPDRSA scale that assesses Parkinson's motor and non-motor symptoms and their effect on daily life, used by doctors, people with Parkinson's and the FDA alike to judge how well a treatment is working.Learn more, including the part that scores movement symptoms specifically. It also beat the placebo on a combined measure of non-movement symptoms — sleep, fatigue and related issues — where most people on bezisterim held steady or improved while the placebo group tended to get worse. The improvement was most pronounced in participants with high platelet levels, a sign the company says may reflect higher inflammation in the body; bezisterim was well tolerated, with no serious safety issues reported.
✅ If you have Parkinson’s
If non-movement symptoms such as poor sleep or fatigue have felt harder to get help for than tremor or stiffness, this is a drug that was specifically designed with those symptoms in mind, alongside movement symptoms.
🙋 If you’re a care partner
Sleep problems, fatigue and other non-movement symptoms are often the ones that go unmentioned at appointments because they don’t seem as “Parkinson’s-related” as tremor does. This trial is a reminder that they are increasingly a direct target of new treatments, so it’s worth continuing to bring them up.
What you can do now
Both of these point at the disease process rather than only its symptoms, but both still need larger trials — or, for the vaccine, the rest of this one — before they could become something you are actually prescribed. If either sounds relevant to you, it’s worth mentioning at your next appointment: “I read about a treatment aimed at [inflammation / clearing this protein] — is that something worth watching for me?”
ParkinON has rewritten recently published research and news coverage in plain language for this article. It is not a substitute for medical diagnosis or treatment, and it says nothing about whether a treatment is approved or available where you live. If you have questions about a new treatment, please talk with your care team.